Effectiveness of maintenance therapy of lithium vs other mood stabilizers in monotherapy and in combinations: A systematic review of evidence from observational studies
Citation
Kessing, Lars Vedel; Bauer, Michael; Nolen, Willem A; Severus, Emanuel; Goodwin, Guy M; Geddes, John. Effectiveness of maintenance therapy of lithium vs other mood stabilizers in monotherapy and in combinations: A systematic review of evidence from observational studies. Bipolar Disorders; Feb 2018. 20:419–431.
Abstract
Objectives: For the first time to present a systematic review of observational studies on the efficiency of lithium
monotherapy in comparison with other maintenance mood stabilizers in monotherapy and in combination.
Methods: As part of the International Society for Bipolar Disorders (ISBD) Task Force on Lithium Treatment, we
undertook a systematic literature search of non-randomized controlled observational studies on (i) lithium
monotherapy vs treatment with another maintenance mood stabilizer in monotherapy and (ii) lithium in
combination with other mood stabilizers vs monotherapy. Results: In eight out of nine identified studies
including a total of < 14 000 patients, maintenance lithium monotherapy was associated with improved
outcome compared with another mood stabilizer in monotherapy, including valproate, lamotrigine, olanzapine,
quetiapine, unspecified anticonvulsants, carbamazepine/lamotrigine, unspecified atypical antipsychotics and
unspecified antipsychotics. Among the four identified studies including a total of > 4000 patients comparing
maintenance combination therapy with maintenance monotherapy, a few combination therapies were found to
be superior to monotherapy in some analyses, but many were not. Conclusions: The results show the superiority
in real life of lithium monotherapy compared with monotherapy with other maintenance mood stabilizers. The
four largest register-based studies largely addressed confounding, but, as ever, residual confounding cannot be
excluded. Nevertheless, the observational findings substantially add to the findings from randomized controlled
trials, whose designs often limit the validity of comparison between medicines.
Published online at:
Collections
- Bipolar Disorder [38]